SG11202012930RA - Triazole glycolate oxidase inhibitors - Google Patents
Triazole glycolate oxidase inhibitorsInfo
- Publication number
- SG11202012930RA SG11202012930RA SG11202012930RA SG11202012930RA SG11202012930RA SG 11202012930R A SG11202012930R A SG 11202012930RA SG 11202012930R A SG11202012930R A SG 11202012930RA SG 11202012930R A SG11202012930R A SG 11202012930RA SG 11202012930R A SG11202012930R A SG 11202012930RA
- Authority
- SG
- Singapore
- Prior art keywords
- triazole
- oxidase inhibitors
- glycolate oxidase
- glycolate
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862694918P | 2018-07-06 | 2018-07-06 | |
| US201962827573P | 2019-04-01 | 2019-04-01 | |
| PCT/US2019/040690 WO2020010309A1 (en) | 2018-07-06 | 2019-07-05 | Triazole glycolate oxidase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012930RA true SG11202012930RA (en) | 2021-01-28 |
Family
ID=67441692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012930RA SG11202012930RA (en) | 2018-07-06 | 2019-07-05 | Triazole glycolate oxidase inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11401246B2 (en) |
| EP (1) | EP3817816A1 (en) |
| JP (1) | JP7348705B2 (en) |
| KR (1) | KR20210041564A (en) |
| CN (1) | CN112399873A (en) |
| AU (1) | AU2019297523A1 (en) |
| BR (1) | BR112021000050A2 (en) |
| CA (1) | CA3104529A1 (en) |
| CO (1) | CO2021001277A2 (en) |
| IL (1) | IL279952A (en) |
| MX (1) | MX2021000051A (en) |
| PE (1) | PE20210859A1 (en) |
| SG (1) | SG11202012930RA (en) |
| WO (1) | WO2020010309A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021000051A (en) | 2018-07-06 | 2021-03-25 | Cantero Therapeutics Inc | Triazole glycolate oxidase inhibitors. |
| AU2020376792A1 (en) | 2019-11-01 | 2022-05-26 | Lilac Therapeutics, Inc. | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors |
| EP4087836A1 (en) * | 2020-01-08 | 2022-11-16 | Cantero Therapeutics, Inc. | Processes for preparing triazole glycolate oxidase inhibitors |
| WO2022066933A1 (en) * | 2020-09-24 | 2022-03-31 | Chinook Therapeutics Canada, Inc. | Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof |
| CA3234440A1 (en) * | 2021-10-11 | 2023-04-20 | Jonathan C. Fox | 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0774218B2 (en) * | 1987-03-02 | 1995-08-09 | 第一製薬株式会社 | Benzopyranotriazole derivative |
| US6187326B1 (en) | 1998-12-29 | 2001-02-13 | Thomas T. Yamashita | Soil amendment composition |
| US7022702B2 (en) | 2000-04-07 | 2006-04-04 | Qlt Inc. | Antiproliferative 1,2,3-thiadiazole compounds |
| AU2004293019B2 (en) | 2003-11-19 | 2010-10-28 | Array Biopharma Inc. | Bicyclic inhibitors of MEK and methods of use thereof |
| CA2580845A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| JP6109192B2 (en) | 2012-01-10 | 2017-04-05 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Pyridazine amide compounds and their use as SYK inhibitors |
| CN103906427B (en) | 2012-10-25 | 2015-12-02 | 朝日集团控股株式会社 | The method for increasing of latex |
| US20140213538A1 (en) | 2013-01-15 | 2014-07-31 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| US9392796B2 (en) | 2013-03-15 | 2016-07-19 | Spogen Biotech Inc. | Plant growth-promoting bacteria and methods of use |
| FR3021843B1 (en) | 2014-06-06 | 2016-07-08 | Lesaffre & Cie | METHOD AND COMPOSITION FOR IMPROVING THE PRODUCTIVITY OF NON-LEGUMINOUS PLANTS |
| JP5866035B1 (en) | 2015-01-08 | 2016-02-17 | アサヒグループホールディングス株式会社 | Effective tillering promotion method |
| CN107404883A (en) | 2015-03-19 | 2017-11-28 | 兴人生命科学株式会社 | Promote with plant growth or root extends facilitation effect and added value improves the yeast extract of effect |
| WO2017100266A1 (en) | 2015-12-07 | 2017-06-15 | Wake Forest University Health Sciences | Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones |
| EP3731840A4 (en) | 2017-12-29 | 2021-09-15 | Orfan Biotech Inc. | Glycolate oxidase inhibitors and use thereof |
| TWI811282B (en) * | 2017-12-29 | 2023-08-11 | 美商拜奧馬林製藥公司 | Glycolate oxidase inhibitors for the treatment of disease |
| US11389456B2 (en) | 2018-02-23 | 2022-07-19 | Oxalurx, Inc. | Compounds and methods for treating oxalate-related diseases |
| MX2021000051A (en) | 2018-07-06 | 2021-03-25 | Cantero Therapeutics Inc | Triazole glycolate oxidase inhibitors. |
| JP2022536969A (en) | 2019-06-19 | 2022-08-22 | ビオマリン プハルマセウトイカル インコーポレイテッド | Glycolate oxidase inhibitors for the treatment of diseases |
-
2019
- 2019-07-05 MX MX2021000051A patent/MX2021000051A/en unknown
- 2019-07-05 US US17/255,600 patent/US11401246B2/en active Active
- 2019-07-05 EP EP19745452.3A patent/EP3817816A1/en active Pending
- 2019-07-05 SG SG11202012930RA patent/SG11202012930RA/en unknown
- 2019-07-05 BR BR112021000050-0A patent/BR112021000050A2/en unknown
- 2019-07-05 CN CN201980045610.4A patent/CN112399873A/en active Pending
- 2019-07-05 CA CA3104529A patent/CA3104529A1/en active Pending
- 2019-07-05 KR KR1020217003486A patent/KR20210041564A/en unknown
- 2019-07-05 PE PE2021000011A patent/PE20210859A1/en unknown
- 2019-07-05 AU AU2019297523A patent/AU2019297523A1/en active Pending
- 2019-07-05 WO PCT/US2019/040690 patent/WO2020010309A1/en active Application Filing
- 2019-07-05 JP JP2021521945A patent/JP7348705B2/en active Active
-
2021
- 2021-01-04 IL IL279952A patent/IL279952A/en unknown
- 2021-02-05 CO CONC2021/0001277A patent/CO2021001277A2/en unknown
-
2022
- 2022-06-17 US US17/843,455 patent/US20230143491A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230143491A1 (en) | 2023-05-11 |
| US11401246B2 (en) | 2022-08-02 |
| WO2020010309A1 (en) | 2020-01-09 |
| CN112399873A (en) | 2021-02-23 |
| US20210403439A1 (en) | 2021-12-30 |
| PE20210859A1 (en) | 2021-05-18 |
| CA3104529A1 (en) | 2020-01-09 |
| KR20210041564A (en) | 2021-04-15 |
| JP2021530560A (en) | 2021-11-11 |
| BR112021000050A2 (en) | 2021-04-06 |
| CO2021001277A2 (en) | 2021-04-30 |
| WO2020010309A9 (en) | 2020-01-30 |
| EP3817816A1 (en) | 2021-05-12 |
| IL279952A (en) | 2021-03-01 |
| MX2021000051A (en) | 2021-03-25 |
| AU2019297523A1 (en) | 2021-02-25 |
| JP7348705B2 (en) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | Kif18a inhibitors | |
| IL290341A (en) | Mta-cooperative prmt5 inhibitors | |
| IL277006A (en) | Cd73 inhibitors | |
| IL279952A (en) | Triazole glycolate oxidase inhibitors | |
| IL304348A (en) | Cd73 inhibitors | |
| GB201807014D0 (en) | Factor xlla inhibitors | |
| IL289914A (en) | Enzyme inhibitors | |
| EP4051688A4 (en) | Cd73 inhibitors | |
| SG11202110534QA (en) | Cd73 inhibitors | |
| IL276013A (en) | Pi4kiiibeta inhibitors | |
| IL289863A (en) | Enzyme inhibitors | |
| IL289778A (en) | Enzyme inhibitors | |
| IL289783A (en) | Enzyme inhibitors | |
| ZA202109573B (en) | Prmt5 inhibitors | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| IL277806A (en) | Growth inhibitor | |
| EP4081199A4 (en) | Lipoxygenase inhibitors | |
| EP3768256A4 (en) | Pan-tropic entry inhibitors | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| IL291456A (en) | Growth inhibitor | |
| GB201812462D0 (en) | Inhibitors | |
| GB201905370D0 (en) | Elastate inhibition | |
| GB201809939D0 (en) | Eastase inhibitor | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors |